Barbora De Courten (Associate Professor at Monash University, Melbourne, Australia) discusses the latest studies into carnosine supplementation in diabetes prevention at ADA 2018. Carnosine is food supplement and has been shown in animal studies to prevent and be useful in the treatment of type 2 diabetes. It has been show to have anti-inflammatory, anti-oxidative, and anti-advanced glycation end product properties that are important mechanisms in type 2 diabetes and related diseases. The study presented at this meeting showed the effect of carnosine supplementation on cardiometabolic risk factors in obesity, prediabetes and diabetes.
1. What is carnosine? (0:14)
2. What is the rationale behind its use in the prevention of diabetes? (0:35)
3. What are the key findings of your study around the effect of carnosine supplementation on cardiometabolic risk factors in obesity, prediabetes and diabetes? (1:21)
4. What are the key challenges in preventing diabetes? (1:49)
Filmed at ADA 2018, Orlando, FL, US
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021: Anticipated Congress Highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!